Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Rapid Micro Biosystems Inc (RPID)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: RPID (3-star) is a SELL. SELL since 5 days. Profits (16.44%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8
1 Year Target Price $8
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 113.2% | Avg. Invested days 39 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 123.61M USD | Price to earnings Ratio - | 1Y Target Price 8 |
Price to earnings Ratio - | 1Y Target Price 8 | ||
Volume (30-day avg) 3 | Beta 1.33 | 52 Weeks Range 0.80 - 4.50 | Updated Date 08/15/2025 |
52 Weeks Range 0.80 - 4.50 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-01 | When - | Estimate -0.26 | Actual -0.27 |
Profitability
Profit Margin -145.63% | Operating Margin (TTM) -167.28% |
Management Effectiveness
Return on Assets (TTM) -29.89% | Return on Equity (TTM) -59.16% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 97929396 | Price to Sales(TTM) 4.08 |
Enterprise Value 97929396 | Price to Sales(TTM) 4.08 | ||
Enterprise Value to Revenue 3.23 | Enterprise Value to EBITDA 0.82 | Shares Outstanding 39332200 | Shares Floating 19310520 |
Shares Outstanding 39332200 | Shares Floating 19310520 | ||
Percent Insiders 10.73 | Percent Institutions 59.26 |
Upturn AI SWOT
Rapid Micro Biosystems Inc
Company Overview
History and Background
Rapid Micro Biosystems Inc. (RPID) was founded in 2006. It focuses on developing and commercializing automated, high-throughput systems for rapid microbial detection, primarily used in biopharmaceutical manufacturing.
Core Business Areas
- Growth Direct Platform: The Growth Direct platform is the core of Rapid Micro Biosystems' business. It's an automated system for rapid detection and enumeration of microorganisms, primarily used in quality control testing during biopharmaceutical manufacturing.
Leadership and Structure
Robert Spignesi is the President and CEO. The company has a typical corporate structure with departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- Growth Direct System: An automated system for rapid microbial detection. While specific market share data is not readily available, it competes with traditional methods and other rapid microbial detection technologies. Competitors include bioMu00e9rieux, Charles River Laboratories, and MilliporeSigma. The system automates and accelerates QC microbial testing, significantly reducing time to results and improving data quality.
Market Dynamics
Industry Overview
The biopharmaceutical quality control testing market is growing due to increasing demand for biologics and stringent regulatory requirements.
Positioning
Rapid Micro Biosystems is positioned as a provider of innovative, automated microbial detection solutions, offering advantages in speed, accuracy, and data management compared to traditional methods. The company targets biopharmaceutical manufacturers seeking to improve efficiency and reduce risks in their QC processes.
Total Addressable Market (TAM)
The TAM is estimated to be in the billions of dollars, encompassing all QC microbial testing in biopharmaceutical manufacturing. Rapid Micro Biosystems is positioned to capture a significant portion of this market with its automated solutions.
Upturn SWOT Analysis
Strengths
- Automated technology
- Faster time to results
- Improved data accuracy
- Reduced labor costs for customers
Weaknesses
- High initial capital investment for customers
- Limited product portfolio
- Dependence on biopharmaceutical industry
- Slower adoption than expected of automated systems
Opportunities
- Expanding into new applications (e.g., cell therapy)
- Geographic expansion
- Partnerships with other technology providers
- Increased regulatory pressure for faster testing
Threats
- Competition from established players
- Economic downturn affecting capital spending
- Technological obsolescence
- Pricing pressure
Competitors and Market Share
Key Competitors
- BIO
- CRL
- MDBX
Competitive Landscape
Rapid Micro Biosystems offers a compelling value proposition with its automated technology but faces competition from larger, more established players with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced revenue growth in recent years.
Future Projections: Analyst estimates suggest continued revenue growth, driven by adoption of automated microbial detection systems. However, profitability is not expected in the near term.
Recent Initiatives: Focus on expanding sales and marketing efforts, and developing new applications for the Growth Direct platform.
Summary
Rapid Micro Biosystems shows promise with its innovative technology and growing revenues, but it is not yet profitable and relies on cash flow. The company has the opportunity to capitalize on a growing need for automation in the biopharmaceutical industry. The company needs to focus on reducing cash burn and expanding its customer base. Increased adoption and sales are crucial for long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is based on estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapid Micro Biosystems Inc
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2021-07-15 | CEO, President & Director Mr. Robert G. Spignesi Jr. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 163 | Website https://www.rapidmicrobio.com |
Full time employees 163 | Website https://www.rapidmicrobio.com | ||
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes growth direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus Mold Alarm software; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.